Monthly Archives: March 2010
NeurOp announces collaboration with Bristol-Myers Squibb
NeurOp Corporation has announced a collaboration with Bristol-Myers Squibb focused on the development of NeurOp’s proprietary small molecules for use in the treatment of major depression and other central nervous system disorders. Under the terms of the agreement, Bristol-Myers Squibb … Continue reading
Filed under alliances
AgaMatrix and sanofi-aventis sign diabetes partnership
AgAgaMatrix and sanofi-aventis have announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop solutions in diabetes management that incorporate … Continue reading
Filed under alliances
Dicerna Pharmaceuticals and Ipsen to collaborate
Ipsen and Dicerna Pharmaceuticals have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA research and peptide engineering. Under the research collaboration agreement the companies will develop novel conjugates of Dicerna’s DsiRNA molecules and … Continue reading
Filed under alliances
Merck partners with Sage Bionetworks
Sage Bionetworks has announced a collaboration with Merck to integrate large molecular and clinical datasets related to metabolic and cardiovascular disease. Sage and Merck will collaborate to create network-based computational models of disease that are designed yo contribute to Merck’s … Continue reading
Filed under alliances
Merck Serono ends partnership with Lpath
The San Diego Business Journal has reported that Merck Serono has ended a partnership with Lpath. According to the report, Lpath’s board of directors had rejected a request by Merck which would have allowed the company additional time to weigh … Continue reading
Filed under alliances
MannKind hits all MMRF milestones
The Multiple Myeloma Research Foundation and MannKind have announced that MannKind has successfully achieved all milestones of a research agreement with MMRF to develop an inhibitor for the treatment of multiple myeloma. The MMRF awarded MannKind a $1 million grant … Continue reading
Filed under Research
GenVec discontinues phase 3 clinical trial of TNFerade
GenVec has announced that it is discontinuing its Phase 3 clinical trial of TNFerade in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds … Continue reading
Filed under alliances
Silence Therapeutics and Dainippon Sumitomo expand siRNA collaboration
Silence Therapeutics has announced that it and Dainippon Sumitomo Pharma have agreed to an expansion of their ongoing small interfering RNA delivery collaboration. Under this collaboration, which was signed in August 2009, the companies are using Silence’s siRNA molecules and … Continue reading
Filed under alliances
Merck merger increases appetite for partnerships
PharmaTimes reports Margaret Beer, head of licensing and external research in Europe for Merck Sharp & Dohme, as commenting that she expects that the newly-expanded company, fresh from its acquisition of Schering-Plough, will have an increased appetite for partnerships.
Filed under alliances
Medivation cuts staff
Medivation has announced that, following the failure this month of dimebon in trials, the company is implementing a plan to reduce its workforce and operating costs in order to focus its resources on prioritized dimebon trials and the continued development … Continue reading
Filed under alliances
